<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870205</url>
  </required_header>
  <id_info>
    <org_study_id>GPL/CT/2015/004/III</org_study_id>
    <secondary_id>Study Number: GSP 301-304</secondary_id>
    <nct_id>NCT02870205</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)</brief_title>
  <acronym>GSP 301-304</acronym>
  <official_title>A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Specialty S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Specialty S.A.</source>
  <brief_summary>
    <textblock>
      Study to evaluate the efficacy, safety and tolerability of GSP 301 NS compared with placebo
      NS and individual monotherapy formulations for the treatment of Seasonal Allergic Rhinitis
      (subjects 12 years of age and older)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS)</measure>
    <time_frame>Baseline and day 14</time_frame>
    <description>The Reflective Total Nasal Symptom Score (rTNSS) was assessed by 12-hour reflective scoring of the severity of four nasal symptoms (rhinorrhea, sneezing, nasal congestion, nasal itching). Symptom scores ranged from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate). The rTNSS was calculated as the sum of the subject-reported severity scores for nasal symptoms, and value ranged from 0 (no signs/symptoms evident) to 12 (severe signs/symptoms that is hard to tolerate).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1176</enrollment>
  <condition>Seasonal Allergic Rhinitis (SAR)</condition>
  <arm_group>
    <arm_group_label>GSP 301 NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GOM-NS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GMM-2 NS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSP 301 placebo NS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301 NS</intervention_name>
    <description>2 spray in each nostril twice daily for 14 days</description>
    <arm_group_label>GSP 301 NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GOM-NS</intervention_name>
    <description>2 spray in each nostril twice daily for 14 days</description>
    <arm_group_label>GOM-NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMM-2 NS</intervention_name>
    <description>2 spray in each nostril twice daily for 14 days</description>
    <arm_group_label>GMM-2 NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSP 301 placebo NS</intervention_name>
    <description>2 spray in each nostril twice daily for 14 days</description>
    <arm_group_label>GSP 301 placebo NS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant females who are 12 years of age and older.

          -  Documented clinical history of SAR (for at least 2 years preceding the Screening Visit
             [Visit 1]) with exacerbations (clinical evidence of active symptoms) for the relevant
             seasonal allergen during the Fall or mountain cedar allergy seasons (e.g., ragweed or
             mountain cedar pollen)

          -  A 12-hour rTNSS ≥8 out of a possible 12 and a congestion score ≥2 for the AM
             assessment at the Screening Visit (Visit 1).

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  History of anaphylaxis and/or other severe local reaction(s) to skin testing.

          -  History of positive test for HIV, Hepatitis B or Hepatitis C infection.

          -  Documented evidence of acute or significant chronic sinusitis or chronic purulent
             postnasal drip.

          -  Subjects with an active pulmonary disorder or infection.

          -  Subjects with posterior subcapsular cataracts or glaucoma

          -  Plans to travel outside the known pollen area for the investigational site for 24
             hours or longer during the last 7 days of the run-in period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeesh Tantry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site 406</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 414</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 435</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 420</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 444</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 428</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 412</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 436</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 432</name>
      <address>
        <city>South Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 426</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 403</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 443</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 441</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 440</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 405</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 434</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 408</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 418</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 402</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 427</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 419</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States 404</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States 407</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 410</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 424</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 411</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 416</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 415</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 442</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 417</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 421</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 430</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 431</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 433</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 422</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 401</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 413</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 425</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 437</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 400</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 409</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 423</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 439</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://epostersonline.com/acaai2017/node/1113</url>
    <description>Poster presentation at the &quot;2017 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology&quot;</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <results_first_submitted>January 31, 2018</results_first_submitted>
  <results_first_submitted_qc>April 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2018</results_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GSP 301 Placebo NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="P2">
          <title>GSP 301 NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Olopatadine HCl NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="P4">
          <title>Mometasone Furoate NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="294"/>
                <participants group_id="P3" count="294"/>
                <participants group_id="P4" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="284"/>
                <participants group_id="P2" count="289"/>
                <participants group_id="P3" count="287"/>
                <participants group_id="P4" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>GSP 301 placebo NS: Due to repeated participation of same subject in 2 seasons, only 1 participation (fall period) was included; Mometasone furoate NS: 1 subject received wrong kit and was excluded; GSP 301 NS and olopatadine HCl NS: Due to coinciding participation of same subject at 2 different sites, both participation's were excluded.</population>
      <group_list>
        <group group_id="B1">
          <title>GSP 301 Placebo NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>GSP 301 NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Olopatadine HCl NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Mometasone Furoate NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="293"/>
            <count group_id="B2" value="293"/>
            <count group_id="B3" value="293"/>
            <count group_id="B4" value="293"/>
            <count group_id="B5" value="1172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="14.93"/>
                    <measurement group_id="B2" value="39.9" spread="14.91"/>
                    <measurement group_id="B3" value="39.9" spread="14.62"/>
                    <measurement group_id="B4" value="39.2" spread="14.86"/>
                    <measurement group_id="B5" value="39.6" spread="14.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="170"/>
                    <measurement group_id="B5" value="737"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS)</title>
        <description>The Reflective Total Nasal Symptom Score (rTNSS) was assessed by 12-hour reflective scoring of the severity of four nasal symptoms (rhinorrhea, sneezing, nasal congestion, nasal itching). Symptom scores ranged from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate). The rTNSS was calculated as the sum of the subject-reported severity scores for nasal symptoms, and value ranged from 0 (no signs/symptoms evident) to 12 (severe signs/symptoms that is hard to tolerate).</description>
        <time_frame>Baseline and day 14</time_frame>
        <population>The FAS was defined as all subjects who were randomized and received at least one dose of investigational product and had at least one post-baseline primary efficacy assessment. This was the primary analysis set for efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>GSP 301 Placebo NS</title>
            <description>2 sprays/nostril twice daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>GSP 301 NS</title>
            <description>2 sprays/nostril twice daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Olopatadine HCl NS</title>
            <description>2 sprays/nostril twice daily for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Mometasone Furoate NS</title>
            <description>2 sprays/nostril twice daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score (rTNSS)</title>
          <description>The Reflective Total Nasal Symptom Score (rTNSS) was assessed by 12-hour reflective scoring of the severity of four nasal symptoms (rhinorrhea, sneezing, nasal congestion, nasal itching). Symptom scores ranged from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate). The rTNSS was calculated as the sum of the subject-reported severity scores for nasal symptoms, and value ranged from 0 (no signs/symptoms evident) to 12 (severe signs/symptoms that is hard to tolerate).</description>
          <population>The FAS was defined as all subjects who were randomized and received at least one dose of investigational product and had at least one post-baseline primary efficacy assessment. This was the primary analysis set for efficacy analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="293"/>
                <count group_id="O4" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="1.2"/>
                    <measurement group_id="O2" value="10.1" spread="1.2"/>
                    <measurement group_id="O3" value="10.2" spread="1.3"/>
                    <measurement group_id="O4" value="10.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.2"/>
                    <measurement group_id="O2" value="-4.3" spread="3.1"/>
                    <measurement group_id="O3" value="-3.6" spread="3.3"/>
                    <measurement group_id="O4" value="-3.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>GSP 301 NS vs GSP 301 placebo NS comparison for rTNSS was tested at 0.05 significance level.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AEs and SAEs were collected from the time of signing the informed consent form until the end of study i.e., 7-10 days of screening and placebo run-in and 14 days of treatment.</time_frame>
      <desc>Mometasone furoate NS: 1 subject received wrong kit and was excluded</desc>
      <group_list>
        <group group_id="E1">
          <title>GSP 301 Placebo NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>GSP 301 NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Olopatadine HCl NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
        <group group_id="E4">
          <title>Mometasone Furoate NS</title>
          <description>2 sprays/nostril twice daily for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="294"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="294"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Per the agreement, Sponsor reserves the right for publishing trial results and the Investigator cannot publish without written consent from the CRO/Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Glenmark Pharmaceuticals Ltd</organization>
      <phone>(201) 684-8000</phone>
      <email>clinicaltrialsdisclosuredesk@glenmarkpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

